ClinicalTrials.gg
Sign In

Lymphoma, Extranodal NK-T-Cell clinical trials

The registry lists 270 studies for Lymphoma, Extranodal NK-T-Cell across more than 10 countries. 36 are recruiting or about to start. 137 of them are mainly about Lymphoma, Extranodal NK-T-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.

Get an email when these change. Save the Lymphoma, Extranodal NK-T-Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
117
Status unknown
49
Terminated
36
Recruiting
20
Not yet recruiting
16
Withdrawn
16

Phase

Phase 2
126
Phase 1
90
Phase 3
14
Phase 4
5
Early Phase 1
5

Where

United States
144
China
73
Korea, Republic of
16
Italy
11
Canada
8
France
8

Who runs them

National Cancer Institute (NCI) (22) · Fred Hutchinson Cancer Center (15) · Mayo Clinic (11) · Sun Yat-sen University (11) · City of Hope Medical Center (9) · Ruijin Hospital (9) · Case Comprehensive Cancer Center (7) · Beijing Tongren Hospital (7)

What is being tested here

Drugs under test in Lymphoma, Extranodal NK-T-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Selinexor202
Golidocitinib202
Fludarabine1019
Busulfan1011
Methotrexate117
Azacitidine104
Thiotepa103
Sintilimab103
Stapokibart101
TR115111

Drug classes tested here Immune checkpoint inhibitors 4 open · Antimetabolites 3 open · Alkylating agents 2 open · Tyrosine kinase inhibitors (TKIs) 2 open · JAK inhibitors 2 open

Coming up

4phase 3 studies under way
7studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7

Who these studies take

Of the 20 Lymphoma, Extranodal NK-T-Cell studies recruiting now, 11 (55%) set no upper age limit and 8 (40%) stop at 75 or younger. 4 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (5%) take healthy volunteers.

Recruiting studies that take each age, of 20
AgeWomenMen
102 (10%)2 (10%)
1818 (90%)18 (90%)
3019 (95%)19 (95%)
4019 (95%)19 (95%)
5019 (95%)19 (95%)
6520 (100%)20 (100%)
7514 (70%)14 (70%)
8512 (60%)12 (60%)

Across all 270 studies, recruiting or not: 41% stop at 75 or younger and 14% at 65; 30% take children; 0% are for women only and 0% for men only; 1% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, Extranodal NK-T-Cell studies take

Of 39 phase 2 interventional studies under Lymphoma, Extranodal NK-T-Cell, half reached primary completion within 64 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 155 mo45–80 · 18 studies——
Phase 264 mo45–99 · 39 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 15, 2026.

Newly registered1

Studies

Recruiting first, then most recently updated. Showing 50 of 270. Browse all 270 → or search them.